Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy, Eur J Cancer, vol.44, issue.1, pp.123-153, 2008. ,
ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting, J Thorac Oncol, vol.9, issue.5, pp.596-611, 2014. ,
Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.26, issue.5, pp.40-55, 2015. ,
Follow-up study of thymomas with special reference to their clinical stages, Cancer, vol.48, issue.11, pp.2485-92, 1981. ,
New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China, Cancer, vol.95, issue.2, pp.420-429, 2002. ,
Prognostic factors and long-term results after thymoma resection: a series of 307 patients, J Thorac Cardiovasc Surg, vol.112, issue.2, p.8751506, 1996. ,
Prognostic factors for cure, recurrence and long-term survival after surgical resection of thymoma, J Thorac Oncol, vol.9, issue.7, pp.1018-1040, 2014. ,
Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single ,
Chemotherapy definitions and policies for thymic malignancies, J Thorac Oncol, vol.6, issue.7, pp.1749-55, 2011. ,
Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial, J Clin Oncol, vol.15, issue.9, pp.3093-3102, 1997. ,
How large databases may impact clinical practices for rare tumorspostoperative chemotherapy in thymic malignancies, Journal of thoracic disease, vol.8, issue.8, pp.1863-1867, 2016. ,
Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma, J Clin Oncol, vol.29, issue.15, pp.2060-2065, 2011. ,
Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group ,
, J Clin Oncol, vol.12, issue.6, pp.1164-1172, 1994.
Eastern Cooperative Oncology Group Phase IIT. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial, J Clin Oncol, vol.22, issue.2, pp.293-302, 2004. ,
Imatinib mesylate in thymic epithelial malignancies, Cancer Chemother Pharmacol, vol.69, issue.2, pp.309-324, 2012. ,
Mutations of epigenetic regulatory genes are common in thymic carcinomas, Scientific reports, vol.4, p.7336, 2014. ,
Massively parallel sequencing identifies recurrent mutations in TP53 in thymic carcinoma associated with poor prognosis, J Thorac Oncol, vol.10, issue.2, pp.373-80, 2015. ,
Bridging with GAPs: receptor communication through RGS proteins. Science's STKE: signal transduction knowledge environment, p.14, 2001. ,
Allelic losses of loci at 3p25.1, 8p22, 13q12, 17p13.3, and 22q13 correlate with postoperative recurrence in breast cancer, Clin Cancer Res, vol.7, issue.4, pp.876-82, 2001. ,
Clusters of chromosomal imbalances in thymic epithelial tumours are associated with the WHO classification and the staging system according to Masaoka, Int J Cancer, vol.105, issue.4, pp.494-502, 2003. ,
Genetic aberrations common in gastric high-grade large B-cell lymphoma, Blood, vol.95, issue.4, pp.1180-1187, 2000. ,
Apoptosis-related (survivin, Bcl-2), tumor suppressor gene (p53), proliferation (Ki-67), and non-receptor tyrosine kinase (Src) markers expression and correlation with clinicopathologic variables in 60 thymic neoplasms, Chest, vol.136, issue.1, pp.220-228, 2009. ,
Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors, Cell death & disease, vol.3, p.351, 2012. ,
PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors, J Thorac Oncol, vol.11, issue.8, pp.1345-56, 2016. ,
Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy. Lung Cancer, vol.89, pp.306-316, 2015. ,
Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy, J Clin Oncol, vol.36, issue.4, pp.342-351, 2018. ,
Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses, Oncotarget, vol.4, issue.6, pp.890-898, 2013. ,
Thymoma and thymic carcinomas, Crit Rev Oncol Hematol, vol.99, pp.332-50, 2016. ,
Crizotinib resistance: implications for therapeutic strategies, Ann Oncol, vol.27, issue.3, pp.42-50, 2016. ,
Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas, Clin Cancer Res, vol.15, issue.22, pp.6790-6799, 2009. ,
Reproducibility of the WHO classification of thymomas: practical implications, Lung Cancer, vol.79, issue.3, pp.236-277, 2013. ,
Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors, Clin Cancer Res, vol.17, issue.8, pp.2237-2286, 2011. ,
Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. The lancet oncology, vol.15, pp.191-200, 2014. ,
Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy, J Clin Oncol, p.2017744078, 2017. ,
Establishment and characterization of a novel cell line derived from human thymoma AB tumor, Lab Invest, vol.92, issue.11, pp.1564-73, 2012. ,
mTORC1 and mTORC2 in cancer and the tumor microenvironment. Oncogene, vol.36, pp.2191-201, 2017. ,
Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas?, J Thorac Oncol, vol.11, issue.8, pp.1197-200, 2016. ,
A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas, Br J Cancer, vol.114, issue.4, pp.477-84, 2016. ,
The Integrated Genomic Landscape of Thymic Epithelial Tumors, Cancer cell, vol.33, issue.2, pp.244-58, 2018. ,